Radiation/Immunotherapy Combinations – Clinical Highlights and Case Discussion - 2021 Annual Meeting
Immunotherapy has been rapidly integrated into oncology practice across multiple disease types. In many cases, it provides a survival advantage compared with cytotoxic chemotherapy in the metastatic setting; immunotherapy is approved for patients with locally advanced lung cancer following chemoradiation therapy; and immunotherapy is being tested in combination with chemoradiation across multiple other disease types.
This course provides clinicians with an update on clinical trial data relevant to combinations of radiation and immune therapy. Through illustrative cases, speakers also go through examples of how the combination is used in clinical practice. Presenters highlight potential safety/toxicity concerns regarding combined therapy, questions regarding the sequencing of radiation and immunotherapy, and cases discussing the use of radiation and immunotherapy in the neoadjuvant, adjuvant, oligometastatic and metastatic setting. A good portion of the course is interactive including case presentations to highlight the potential of radiation immunotherapy combinations already being considered in clinical practice.
This activity is available from December 30, 2021, through 11:59 p.m. Eastern time on December 31, 2024.
This activity was originally recorded at ASTRO’s 2021 Annual Meeting, October 24-27th.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents and medical oncologists.
Upon completion of this activity, participants should be able to:
- Identify potential toxicity concerns regarding immunotherapy / radiation combinations.
- Identify settings where radiation/immunotherapy combinations have proven benefit or are being actively evaluated including in the neoadjuvant, adjuvant, oligometastatic and metastatic settings.
- Discuss potential mechanisms behind potential synergy between radiation and immunotherapy as they apply to clinical practice (e.g. the abscopal effect).
- Jonathan D. Schoenfeld, MD, Bringham and Women's Hospital and receives compensation from Merck, BMS, Debiopharm, ACI Clinical, Regeneron, LEK, Immunitas, STIMIT, and Astelas.
- Ezra Cohen, MD, Moores Cancer Center at UC San Diego Health and receives compensation from Merck, Merck Serono, Pfizer and AstraZeneca.
- Florence Kathleen Keane, MD, Partners Healthcare and has investment interest from OncLive and AstraZeneca.
- Andrew Sharabi, MD, PhD, UC San Diego, Moores Cancer Center, Department of Radiation Medicine and Applied Sciences and has investment interest from Toragen Biotechnologies, Pfizer, Varian Medical Systems and AstraZeneca. Dr. Sharabi is a founder of Toragen Biotechnologies and he is a San Diego Center for Precission Immunotherapy Scientific Advisory Committee Member.
- Ramesh Rengan, MD, PhD, FASTRO, FASTRO, University of Washington, Department of Radiation Oncology and has investment interest from IBA and AstraZeneca.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.